CUL7 Antibody

1. Study shows that cullin 7 is highly expressed in breast cancer cells and suggests that positive expression is associated with the malignant phenotype and a predictor of poor prognosis. Cullin 7 is involved in cell proliferation and invasion by regulating the cell cycle and microtubule stability. PMID: 29207184
2. CUL7 expression was associated with EC progression and poor prognosis. CUL7 may promote EMT via the ERKSNAI2 pathway in EC. PMID: 29393450
3. overexpression of Cullin7 plays an important role in the pathogenesis and progression of hepatocellular carcinoma and may be a valuable marker for hepatocellular carcinoma management. PMID: 29207970
4. Hepatocellular carcinoma patients with positive expression for both Rabl3 and Cullin7 had a remarkably shorter survival time compared with patients with negative expression for both proteins. PMID: 28739496
5. our study provided evidence that Cullin7 functions as a novel oncogene in lung cancer and may be a potential therapeutic target for lung cancer management. PMID: 25706399
6. Cullin7 promotes epithelial-mesenchymal transformation of cancer cells. PMID: 27053346
7. We report a family with variable phenotypic features of 3-M syndrome and we describe the prenatal and postnatal growth pattern of two affected sisters with a novel homozygous CUL7 mutation (c.3173-1G>C), showing a pre- and post-natal growth deficiency and a normal cranial circumference. PMID: 26850509
8. report an adult female with 3-M syndrome that was caused by novel compound heterozygous mutations (c.4023-1 G>A in splice acceptor site of exon 22 and c.4359_4363dupGGCTG in exon 23) in the CUL7 gene PMID: 26488604
9. Cullin7 may serve as an indicator of poor prognosis in patients with epithelial ovarian cancer. PMID: 26962950
10. study provided evidence that Cullin7 functions as a novel oncogene in breast cancer and may be a potential therapeutic target for breast cancer management PMID: 25003318
11. CUL7, OBSL1 and CCDC8 modulate the alternative splicing of the INSR PMID: 24711643
12. The CUL7, OBSL1, and CCDC8 proteins form a 3M complex that functions in maintaining microtubule and genome integrity and normal development. PMID: 24793695
13. CUL7/Fbxw8 ubiquitin ligase-mediated HPK1 degradation revealed a direct link and novel role of CUL7/Fbxw8 ubiquitin ligase in the MAPK pathway, which plays a critical role in cell proliferation and differentiation. PMID: 24362026
14. Homozygous deletion in exon 18 of the CUL7 gene, which has not been previously described, could be responsible for the 3-M syndrome. PMID: 23517720
15. This study demonstrates specific genomic alterations in HCC/MS and points to CUL7 as a novel gene potentially involved in liver carcinogenesis associated with metabolic Syndrome, the amplification of which might influence cell proliferation. PMID: 22942238
16. Dysregulation of Cul7 and Fbxw8 expression might affect trophoblast turnover in intrauterine growth restriction. PMID: 22524683
17. Mutations in CUL7, OBSL1 and CCDC8 in 3-M syndrome lead to disordered growth factor signalling. PMID: 23018678
18. Growth factor-stimulated TBC1D3 ubiquitination and degradation are regulated by its interaction with CUL7-Fbw8. PMID: 23029530
19. discussion of roles of CUL7, OBSL1 (obscurin-like 1), and CCDC8 (coiled-coil domain containing protein 8) in growth and development using findings from patients with Miller-McKusick-Malvaux syndrome and Silver-Russell syndrome [REVIEW] PMID: 22156540
20. We propose that CUL7, OBSL1, and CCDC8 are members of a pathway controlling mammalian growth. PMID: 21737058
21. CUL7 appears to be the major gene responsible for 3M syndrome accounting for 77.5% of cases while OBSL1 mutations accounts for 16.3%[review] PMID: 21396581
22. CUL7 expression in placenta is up-regulated up to 10 times in intra-uterine growth restriction (IUGR) and up to 15 times in preeclampsia associated with IUGR; the CUL7 promoter is hypomethylated in IUGR. PMID: 20005570
23. 25 distinct mutations in the gene cullin 7 mappped to chromosome 6 were identified in 29 families with 3-M syndrome. PMID: 16142236
24. CUL7 functions to promote cell growth through, in part, antagonizing the function of p53 PMID: 16547496
25. p53-binding domain of CUL7 contributes to the cytoplasmic localization of CUL7 PMID: 16875676
26. CPH domain interaction surface of p53 resides in the tetramerization domain and is formed by residues contributed by at least two subunits PMID: 17298945
27. PARC and CUL7 subcomplexes exhibit E3 ubiquitin ligase activity in vitro. PMID: 17332328
28. In a proteomic screen for p53 interactors the cullin protein Cul7 efficiently associates with p53. PMID: 17586686
29. A novel homozygous 4582insT mutation in CUL7 resulted in a frameshift mutation & a premature stop codon at 1553 (Q1553X)in Yakuts with short stature syndromes. PMID: 17675530
30. CUL7 is a new oncogene that cooperates with Myc in transformation by blocking Myc-induced apoptosis in a p53-dependent manner. PMID: 17942889
31. in 33 novel cases of 3M syndrome, we identified deleterious CUL7 mutations in 23/33 patients, including 19 novel mutations & 1 paternal isodisomy of chromosome 6 encompassing a CUL7 mutation; findings also support genetic heterogeneity of this disease PMID: 19225462

Show More

Hide All

HGNC: 21024

OMIM: 273750

KEGG: hsa:9820

STRING: 9606.ENSP00000438788

UniGene: Hs.520136